Unmasking the lung cancer epigenome

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• Epigenetic reprogramming, involving DNA methylation and chromatin remodeling, is crucial in lung cancer development.
• Silencing of genes and microRNAs by epigenetic mechanisms affects major cell regulatory pathways.
• The reversibility of epigenetic changes offers potential for therapeutic intervention.

Purpose of the Study:

• To review progress in identifying epigenetically silenced genes and microRNAs in lung cancer.
• To highlight the impact of these epigenetic alterations on cell phenotype and signaling pathways.
• To discuss novel therapeutic strategies for epigenetic modification in lung cancer.

Main Methods:

• Utilizing an in vitro model with immortalized human bronchial epithelial cells to identify premalignant epigenetic silencing.
• Employing an in vivo orthotopic nude rat lung cancer model to assess responses to epigenetic therapy.
• Reviewing advancements in understanding epigenetic mechanisms in lung cancer.

Main Results:

• Identification of specific genes and microRNAs epigenetically silenced in lung cancer.
• Demonstration of how loss of function impacts cellular phenotype and signaling pathways.
• Evaluation of epigenetic therapy efficacy in preclinical models.

Conclusions:

• Epigenetic silencing is a key driver in lung cancer initiation and progression.
• Epigenetic modifications are reversible, offering therapeutic opportunities.
• Novel approaches like aerosol delivery and tumor priming show potential for lung cancer treatment.